1. history of hypersensitivity or allergy to any of the components of the vaccine. 2. history of severe anaphylactic reactions from any cause. 3. history of seizures. 4. uncontrolled chronic diseases. 5. chronic diseases that require management with immunosuppressive agents or immune response modulators (eg, systemic corticosteroids, cyclosporine, rituximab among others). 6. oncological disease. 7. active participation, or during the last 3 months in any other clinical study or research experimental intervention. 8. use within 30 days prior to screening evaluation of any drug or herbal supplement, or alternative medicine (for example, transfer factor, chlorine dioxide, etc.) aimed at treating or preventing complications or contagion by sars-cov-2, or any other condition. 9. febrile illness at the time of the screening visit. 10. have received any vaccine (experimental or approved) during the 60 days prior to the scrutiny visit. 11. having received a blood transfusion or blood components during the last 4 months prior to the scrutiny hearing. 12. have been a plasma donor during the last 4 months prior to the visit of scrutiny. 13. have undergone dialysis or hemodialysis procedures during the last year prior to the scrutiny visit. 14. work on poultry or gamecock farms. 15. history of substance abuse problems that in the opinion of the investigator could interfere with the subject's ability to adequately comply with the protocol guidelines.

1. history of hypersensitivity or allergy to any of the components of the vaccine. 2. history of severe anaphylactic reactions from any cause. 3. history of seizures. 4. uncontrolled chronic diseases. 5. chronic diseases that require management with immunosuppressive agents or immune response modulators (eg, systemic corticosteroids, cyclosporine, rituximab among others). 6. oncological disease. 7. active participation, or during the last 3 months in any other clinical study or research experimental intervention. 8. use within 30 days prior to screening evaluation of any drug or herbal supplement, or alternative medicine (for example, transfer factor, chlorine dioxide, etc.) aimed at treating or preventing complications or contagion by sars-cov-2, or any other condition. 9. febrile illness at the time of the screening visit. 10. have received any vaccine (experimental or approved) during the 60 days prior to the scrutiny visit. 11. having received a blood transfusion or blood components during the last 4 months prior to the scrutiny hearing. 12. have been a plasma donor during the last 4 months prior to the visit of scrutiny. 13. have undergone dialysis or hemodialysis procedures during the last year prior to the scrutiny visit. 14. work on poultry or gamecock farms. 15. history of substance abuse problems that in the opinion of the investigator could interfere with the subject's ability to adequately comply with the protocol guidelines.

history of hypersensitivity or allergy to any of the components of the vaccine. history of severe anaphylactic reactions from any cause. history of seizures. uncontrolled chronic diseases. chronic diseases that require management with immunosuppressive agents or immune response modulators (eg, systemic corticosteroids, cyclosporine, rituximab among others). oncological disease. active participation, or during the last 3 months in any other clinical study or research experimental intervention. use within 30 days prior to screening evaluation of any drug or herbal supplement, or alternative medicine (for example, transfer factor, chlorine dioxide, etc.) aimed at treating or preventing complications or contagion by sars-cov-2, or any other condition. febrile illness at the time of the screening visit. have received any vaccine (experimental or approved) during the 60 days prior to the scrutiny visit. having received a blood transfusion or blood components during the last 4 months prior to the scrutiny hearing. have been a plasma donor during the last 4 months prior to the visit of scrutiny. have undergone dialysis or hemodialysis procedures during the last year prior to the scrutiny visit. work on poultry or gamecock farms. history of substance abuse problems that in the opinion of the investigator could interfere with the subject's ability to adequately comply with the protocol guidelines.

history of hypersensitivity or allergy to any of the components of the vaccine. history of severe anaphylactic reactions from any cause. history of seizures. uncontrolled chronic diseases. chronic diseases that require management with immunosuppressive agents or immune response modulators (eg, systemic corticosteroids, cyclosporine, rituximab among others). oncological disease. active participation, or during the last 3 months in any other clinical study or research experimental intervention. use within 30 days prior to screening evaluation of any drug or herbal supplement, or alternative medicine (for example, transfer factor, chlorine dioxide, etc.) aimed at treating or preventing complications or contagion by sars-cov-2, or any other condition. febrile illness at the time of the screening visit. have received any vaccine (experimental or approved) during the 60 days prior to the scrutiny visit. having received a blood transfusion or blood components during the last 4 months prior to the scrutiny hearing. have been a plasma donor during the last 4 months prior to the visit of scrutiny. have undergone dialysis or hemodialysis procedures during the last year prior to the scrutiny visit. work on poultry or gamecock farms. history of substance abuse problems that in the opinion of the investigator could interfere with the subject's ability to adequately comply with the protocol guidelines.